BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

OXiGENE, Inc. 

230 Third Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-547-5900 Fax: 781-547-6800


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
OXiGENE (OXGN) Announces Preclinical Poster Presentation On Oxi4503 At Upcoming American Society of Hematology Meeting 11/20/2014 2:17:32 PM
OXiGENE (OXGN) Announces Issuance Of European Patent for OXi4503 In Acute Myeloid Leukemia And Other Myeloid Malignancies 11/17/2014 2:43:50 PM
OXiGENE (OXGN) Reports Third Quarter 2014 Financial Results 11/13/2014 8:08:46 AM
OXiGENE (OXGN) Announces Presentation Of Phase 2 Data Confirming That Addition Of Fosbretabulin To Bevacizumab Significantly Increases Progression-Free Survival In Recurrent Ovarian Cancer 11/10/2014 7:24:44 AM
OXiGENE (OXGN) Announces Third Quarter 2014 Earnings Conference Call And Webcast 10/22/2014 7:32:32 AM
OXiGENE (OXGN) Announces First Patient Enrolled In Phase 1b/2 Study Of Fosbretabulin Combined With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer 10/8/2014 7:08:31 AM
OXiGENE (OXGN) Announces Presentation Of Data From The Phase 2 GOG186I Study At The 15th Biennial Meeting Of The International Gynecologic Cancer Society 10/7/2014 7:21:01 AM
OXiGENE (OXGN) Initiates Phase 2 Study Of Fosbretabulin In Gastrointestinal Neuroendocrine Tumors 9/18/2014 7:42:55 AM
OXiGENE (OXGN) Announces Presentation At The Rodman & Renshaw Conference On September 9 8/27/2014 7:57:33 AM
OXiGENE (OXGN) Reports Second Quarter 2014 Financial Results 8/5/2014 3:10:18 PM
12345678910...